NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP
Adaptive Biotechnologies Corporation ADPT
9 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$277.0M
▲ 54.8% vs FY2024
EPS · FY25
$-0.39
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-28.2%
Net margin · FY25
-21.5%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 277.0M
Revenue, FY2025 · full 9-year series below
Revenue
Net income
The company lost 21 cents on every revenue dollar this year.
Per share
USD -0.39
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-28.2%
Return on equity, FY2025
ROE
Operating margin-20.6%
Net margin-21.5%
Return on assets-11.3%
Each USD of equity lost 28 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+23.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+14.3%
+23.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.15B
Shares outstanding, FY2025
Change, 5 years+11.7%
Change, 10 years—
The share count grew 12% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 512.7M
total assets, end of FY2025
Total assetsUSD 512.7M
EquityUSD 218.8M
CashUSD 70.5M
Gross debtUSD 131.2M
Net debtUSD 60.7M
Current ratio3.34×
Net debt stands at 28% of equity.
History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue $B
0.3
0.2
0.2
0.2
0.2
0.1
0.1
0.1
0.0
Operating income $B
−0.1
−0.2
−0.2
−0.2
−0.2
−0.2
−0.1
−0.0
−0.0
EBITDA $B
−0.0
−0.1
−0.2
−0.2
−0.2
−0.1
−0.1
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
·
·
·
·
·
·
Net income $B
−0.1
−0.2
−0.2
−0.2
−0.2
−0.1
−0.1
−0.0
−0.0
EPS, diluted $
−0.39
−1.08
−1.56
−1.40
−1.48
−1.11
−1.01
−3.67
−3.50
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
−28.2
−62.4
−58.3
−37.5
−30.8
−22.3
−43.8
·
·
Shares out B
0.15
0.15
0.15
0.14
0.14
0.14
0.13
0.01
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
25 of 25
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed